Fariborz Bahrami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fariborz Bahrami has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Soheila Ajdary
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
9 shared publications - Farhad Riazi-Rad
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
6 shared publications - Jean Sévigny
Axe Maladies infectieuses et immunitaires Centre de recherche du CHU de Québec – Université Laval Quebec Canada
6 shared publications Fethia Ben Yebdri
Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada; Centre de Recherche du CHU de Québec, CHUL, Québec, QC G1V 4G2, Canada
4 shared publicationsFilip Kukulski
4 shared publications- Mohammad Hossein Alimohammadian
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
4 shared publications
Latest Publications
- 9 May 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 16 (2) , 432-444
PpSP42 and LmSTI1-PpSP42 Recombinant Proteins from Phlebotomus papatasi and Leishmania major Confer Protection Against Leishmania major Infection in BALB/c Mice
Purpose: Cutaneous leishmaniasis (CL), a parasitic skin disease transmitted by sand flies, is characterized by complex interactions between Leishmania parasites and sand fly saliva, influencing both transmission and disease progression. This study investigated the immunogenicity of partial Phlebotomus papatasi salivary protein PpSP42 (or PP42 in short) and a novel recombinant fusion protein composed of Leishmania major stress-inducible protein 1 (LmSTI1) and PP42, produced in Escherichia coli. Methods: BALB/c mice were immunized subcutaneously with the fusion protein or with PP42 subunits separately, using resiquimod as an adjuvant, and subsequently challenged with L. major promastigotes and sand fly salivary gland homogenate. Lesion development and parasite burden as well as immune responses were evaluated by measuring key cytokines (IFN-γ, IL-4, IL-10, TNF-α) and antibodies (IgG, IgG1, IgG2a) up to eight weeks post-challenge. Results: Immunization with either PP42 or the fusion protein significantly attenuated lesion development (30-40% reduction in lesion size after 8 weeks; P<0.001) and parasite burden (∼100-fold lower after 8 weeks; P<0.05) compared to the PBS control. This protection was accompanied by significantly higher levels of IFN-γ and TNF-α (P<0.05 for both). Also, an elevated IgG2a/IgG1 ratio (P<0.01), indicative of a Th1-biased immune response was observed when the fusion protein was used for immunization. Conclusion: These findings suggest while immunization with PP42 protein alone resulted in lesion control and reduced parasite load, compared to the control group, these effects were less pronounced than those observed in the fusion protein group. Hence, LmSTI1-PP42 fusion protein warrants further investigation as a potential vaccine candidate against L. major infection.
- 9 May 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 16 (2) , 432-444
PpSP42 and LmSTI1-PpSP42 Recombinant Proteins from Phlebotomus papatasi and Leishmania major Confer Protection Against Leishmania major Infection in BALB/c Mice
Purpose: Cutaneous leishmaniasis (CL), a parasitic skin disease transmitted by sand flies, is characterized by complex interactions between Leishmania parasites and sand fly saliva, influencing both transmission and disease progression. This study investigated the immunogenicity of partial Phlebotomus papatasi salivary protein PpSP42 (or PP42 in short) and a novel recombinant fusion protein composed of Leishmania major stress-inducible protein 1 (LmSTI1) and PP42, produced in Escherichia coli. Methods: BALB/c mice were immunized subcutaneously with the fusion protein or with PP42 subunits separately, using resiquimod as an adjuvant, and subsequently challenged with L. major promastigotes and sand fly salivary gland homogenate. Lesion development and parasite burden as well as immune responses were evaluated by measuring key cytokines (IFN-γ, IL-4, IL-10, TNF-α) and antibodies (IgG, IgG1, IgG2a) up to eight weeks post-challenge. Results: Immunization with either PP42 or the fusion protein significantly attenuated lesion development (30-40% reduction in lesion size after 8 weeks; P<0.001) and parasite burden (∼100-fold lower after 8 weeks; P<0.05) compared to the PBS control. This protection was accompanied by significantly higher levels of IFN-γ and TNF-α (P<0.05 for both). Also, an elevated IgG2a/IgG1 ratio (P<0.01), indicative of a Th1-biased immune response was observed when the fusion protein was used for immunization. Conclusion: These findings suggest while immunization with PP42 protein alone resulted in lesion control and reduced parasite load, compared to the control group, these effects were less pronounced than those observed in the fusion protein group. Hence, LmSTI1-PP42 fusion protein warrants further investigation as a potential vaccine candidate against L. major infection.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1)
P2Y 2 Receptor Controls TLR3‐Induced Chemokine Production in Intestinal Epithelial Cells
Toll‐like receptors (TLRs) and P2 receptors are key regulators of innate immunity. During infection, pathogen‐associated molecular patterns (PAMPs) activate TLRs, whereas extracellular nucleotides engage P2 receptors and influence inflammatory responses. Here, we show that polyinosinic:polycytidylic acid (poly[I:C])‐activated TLR3 and P2Y 2 signalling functionally interact in intestinal epithelial cells (IECs) to regulate chemokine production. HT‐29 cells were stimulated with PAMPs, including the TLR3 agonist poly(I:C), in the presence or absence of P2 receptor signalling inhibitors. CXCL8/IL‐8 or CXCL10/IP‐10 secretion was assessed by ELISA and mRNA expression by quantitative real‐time PCR (RT‐qPCR). Primary IECs from P2Y 2 knock‐out (KO) and wild‐type (WT) mice were also treated with poly(I:C), and CXCL1/KC secretion was measured. Poly(I:C) stimulation induced robust CXCL8/IL‐8 and CXCL10/IP‐10 release in HT‐29 cells. This response was inhibited by nucleotide scavenging, P2 receptor blockade, and P2Y 2 targeting using either specific antagonists or siRNAs. P2Y 2 was the dominant receptor expressed, and its ligands ATP/UTP constitutively released by these cells amplified CXCL8/IL‐8 production induced by a suboptimal concentration of poly(I:C), while alone they had no effect. In support of these findings, primary IECs from P2Y 2 KO mice secreted significantly less CXCL1/KC than WT controls. Altogether, extracellular nucleotide signalling regulates TLR3‐induced chemokine release in IECs through P2Y 2 receptors.
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1)
Open AccessP2Y 2 Receptor Controls TLR3‐Induced Chemokine Production in Intestinal Epithelial Cells
Toll‐like receptors (TLRs) and P2 receptors are key regulators of innate immunity. During infection, pathogen‐associated molecular patterns (PAMPs) activate TLRs, whereas extracellular nucleotides engage P2 receptors and influence inflammatory responses. Here, we show that polyinosinic:polycytidylic acid (poly[I:C])‐activated TLR3 and P2Y 2 signalling functionally interact in intestinal epithelial cells (IECs) to regulate chemokine production. HT‐29 cells were stimulated with PAMPs, including the TLR3 agonist poly(I:C), in the presence or absence of P2 receptor signalling inhibitors. CXCL8/IL‐8 or CXCL10/IP‐10 secretion was assessed by ELISA and mRNA expression by quantitative real‐time PCR (RT‐qPCR). Primary IECs from P2Y 2 knock‐out (KO) and wild‐type (WT) mice were also treated with poly(I:C), and CXCL1/KC secretion was measured. Poly(I:C) stimulation induced robust CXCL8/IL‐8 and CXCL10/IP‐10 release in HT‐29 cells. This response was inhibited by nucleotide scavenging, P2 receptor blockade, and P2Y 2 targeting using either specific antagonists or siRNAs. P2Y 2 was the dominant receptor expressed, and its ligands ATP/UTP constitutively released by these cells amplified CXCL8/IL‐8 production induced by a suboptimal concentration of poly(I:C), while alone they had no effect. In support of these findings, primary IECs from P2Y 2 KO mice secreted significantly less CXCL1/KC than WT controls. Altogether, extracellular nucleotide signalling regulates TLR3‐induced chemokine release in IECs through P2Y 2 receptors.
- 10 April 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 204, 107566
Robust immune responses to intranasal vaccine targeting Bordetella pertussis antigens to claudin-4 on mucosal microfold cells
- 10 April 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 204, 107566
Robust immune responses to intranasal vaccine targeting Bordetella pertussis antigens to claudin-4 on mucosal microfold cells
- 1 January 2025
- Published by National Academy of Sciences of Tajikistan
- Vol. 29 (1) , 68-81
Unraveling Leishmania major Metacyclogenesis: A Comprehensive Analysis of Transcriptomic and Metabolomic Profiles
- 1 January 2025
- Published by National Academy of Sciences of Tajikistan
- Vol. 29 (1) , 68-81
Unraveling Leishmania major Metacyclogenesis: A Comprehensive Analysis of Transcriptomic and Metabolomic Profiles
- Open Access
- 1 September 2024
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 27 (9) , 530-537
In Commemoration of Dr. Farrokh Modabber: An Iranian Pioneer of Cellular Immunology, and Leishmaniases Vaccine Research in Iran and the World
Born in 1940 in Rasht, Iran, Dr. Farrokh Modabber earned his B.A. in Bacteriology and Ph.D. in Microbiology from University of California, Los Angeles (UCLA). He joined the Harvard Medical School as a fellow before transitioning to a faculty role at Harvard School of Public Health (HSPH) and played a pivotal role in advancing Cellular Immunology. In the early 1970s, he returned to Iran as an Associate Professor at Pahlavi University in Shiraz. Subsequently, he rejoined HSPH before embarking on a tenure at Tehran University. As the head of the Pathobiology Department at Tehran University School of Public Health, he initiated the Tehran/Harvard joint M.Sc. program in Immunology, which played a crucial role in shaping the careers of numerous Iranian immunologists over the following decades. Dr. Modabber went on to hold esteemed positions such as Director General of the Pasteur Institute of Iran, visiting immunology lecturer at various universities, Coordinator of Research Capability Strengthening of WHO’s Special Program for Research and Training in Tropical Diseases (TDR), Director of the Infectious Disease Research Institute (IDRI), and Senior Advisor of Drugs for Neglected Diseases initiative (DNDi), to name a few. This article highlights Dr. Modabber’s impactful career, focusing on his efforts to combat global leishmaniasis.
- 1 September 2024
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 27 (9) , 530-537
Open AccessIn Commemoration of Dr. Farrokh Modabber: An Iranian Pioneer of Cellular Immunology, and Leishmaniases Vaccine Research in Iran and the World
Born in 1940 in Rasht, Iran, Dr. Farrokh Modabber earned his B.A. in Bacteriology and Ph.D. in Microbiology from University of California, Los Angeles (UCLA). He joined the Harvard Medical School as a fellow before transitioning to a faculty role at Harvard School of Public Health (HSPH) and played a pivotal role in advancing Cellular Immunology. In the early 1970s, he returned to Iran as an Associate Professor at Pahlavi University in Shiraz. Subsequently, he rejoined HSPH before embarking on a tenure at Tehran University. As the head of the Pathobiology Department at Tehran University School of Public Health, he initiated the Tehran/Harvard joint M.Sc. program in Immunology, which played a crucial role in shaping the careers of numerous Iranian immunologists over the following decades. Dr. Modabber went on to hold esteemed positions such as Director General of the Pasteur Institute of Iran, visiting immunology lecturer at various universities, Coordinator of Research Capability Strengthening of WHO’s Special Program for Research and Training in Tropical Diseases (TDR), Director of the Infectious Disease Research Institute (IDRI), and Senior Advisor of Drugs for Neglected Diseases initiative (DNDi), to name a few. This article highlights Dr. Modabber’s impactful career, focusing on his efforts to combat global leishmaniasis.
- 4 March 2022
- Published by Taylor & Francis in Expert Review of Proteomics
- Vol. 19 (3) , 213-225
Cutaneous leishmaniasis: multiomics approaches to unravel the role of immune cells checkpoints
Cutaneous leishmaniasis (CL) is the most frequent form of leishmaniases, associated with skin inflammation and ulceration. Understanding the interaction of different phagocytic cells in the recogni...
- 4 March 2022
- Published by Taylor & Francis in Expert Review of Proteomics
- Vol. 19 (3) , 213-225
Cutaneous leishmaniasis: multiomics approaches to unravel the role of immune cells checkpoints
Cutaneous leishmaniasis (CL) is the most frequent form of leishmaniases, associated with skin inflammation and ulceration. Understanding the interaction of different phagocytic cells in the recogni...
- Open Access
- 1 March 2022
- Vol. 26 (2) , 91-98
Dr. Abolghasem Bahrami (1894-1950): Physician, Pasteurian, and a Pioneer of Microbiology and Public Health Planning in Iran
Dr. Abolghasem Bahrami was among the generation of Iranian scientists in the early twentieth century who gained most of their knowledge through resources available inside the country. Educated at Dar-ul-Funun Medical School, he was a physician with a great talent in learning, especially self-teaching natural sciences and European languages. He joined the Pasteur Institute of Iran (IPI) at the early days of its foundation and became an integral contributor to this institution during the first twenty-five years of its mission. One of his first assignments at IPI was to help initiating an anti-rabies department by bringing back the rabies vaccine and its manufacturing equipment from Institut Pasteur of Paris. During his IPI years, aside from managerial tasks, he actively participated in upgrading the medical treatments and protocols used for controlling many infectious diseases. He functioned twice as the provisional director of IPI (1925-1926 and 1937-1946) and is considered as the first Iranian director of the Institute. Meanwhile, Dr. Bahrami was a significant contributor to the public health system and assumed several responsibilities such as Chief Quarantine Medical Officer, Chief of Public Health, and the Head of Public Health Administration, in order to improve public health planning throughout the country.
- 1 March 2022
- Vol. 26 (2) , 91-98
Open AccessDr. Abolghasem Bahrami (1894-1950): Physician, Pasteurian, and a Pioneer of Microbiology and Public Health Planning in Iran
Dr. Abolghasem Bahrami was among the generation of Iranian scientists in the early twentieth century who gained most of their knowledge through resources available inside the country. Educated at Dar-ul-Funun Medical School, he was a physician with a great talent in learning, especially self-teaching natural sciences and European languages. He joined the Pasteur Institute of Iran (IPI) at the early days of its foundation and became an integral contributor to this institution during the first twenty-five years of its mission. One of his first assignments at IPI was to help initiating an anti-rabies department by bringing back the rabies vaccine and its manufacturing equipment from Institut Pasteur of Paris. During his IPI years, aside from managerial tasks, he actively participated in upgrading the medical treatments and protocols used for controlling many infectious diseases. He functioned twice as the provisional director of IPI (1925-1926 and 1937-1946) and is considered as the first Iranian director of the Institute. Meanwhile, Dr. Bahrami was a significant contributor to the public health system and assumed several responsibilities such as Chief Quarantine Medical Officer, Chief of Public Health, and the Head of Public Health Administration, in order to improve public health planning throughout the country.
- 1 May 2021
- Published by Elsevier in Acta Tropica
- Vol. 217, 105855
The effects of natural disasters on leishmaniases frequency: A global systematic review and meta-analysis
- 1 May 2021
- Published by Elsevier in Acta Tropica
- Vol. 217, 105855
The effects of natural disasters on leishmaniases frequency: A global systematic review and meta-analysis
- 1 March 2021
- Published by Elsevier in Microbial Pathogenesis
- Vol. 152, 104721
Cutaneous leishmaniasis in Iran: A systematic review and meta-analysis
- 1 March 2021
- Published by Elsevier in Microbial Pathogenesis
- Vol. 152, 104721
Cutaneous leishmaniasis in Iran: A systematic review and meta-analysis
- 21 July 2020
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 39 (16) , 5910-5919
Computational evaluation of a fusion protein consisted of pertussis toxin and filamentous hemagglutinin fromBordetella pertussisto target Claudin-4 using C-terminal fragment ofClostridium perfringensenterotoxin
Pertussis, caused by Bordetella pertussis is still one of the controversial diseases worldwide due to its high prevalence in both the developed and the developing countries, especially among young children. As currently approved vaccines are not protective enough and provide Th2-type immune responses, there is an urgent need to develop new vaccines. In the current study, we applied the C-terminal fragment of Clostridium perferingens enterotoxin (C-CPE) as a delivery system and F1S1 fragment (Filamentous hemagglutinin (F1) and subunit 1 of pertussis toxin (S1) of B. pertussis to design a novel chimeric protein in silico, to target Claudin-4 receptors in mice lung cells. To achieve this goal, the primary, secondary and tertiary structures of the fusion protein were evaluated and the interaction of this protein with Claudin-4 receptors was studied. Molecular dynamic (MD) simulation analysis was performed to investigate the physical movement of atoms in a fixed period. According to the results; the full-length fusion protein has consisted of 807 amino acid residues which could be classified as a stable protein. There was a convenient consistency between the 3D predicted structure and the secondary structure prediction. An acceptable percentage of the residues were also detected in the most favored and allowed regions for the model. Based on HADDOCK results, there were no considerable differences between the interactions and MD simulation analysis, indicating that the predicted structures were stable during the simulation. Altogether, the data reported in this study represents the first step toward developing a nasal vaccine candidate against B. pertussis infection. Communicated by Ramaswamy H. Sarma
- 21 July 2020
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 39 (16) , 5910-5919
Computational evaluation of a fusion protein consisted of pertussis toxin and filamentous hemagglutinin fromBordetella pertussisto target Claudin-4 using C-terminal fragment ofClostridium perfringensenterotoxin
Pertussis, caused by Bordetella pertussis is still one of the controversial diseases worldwide due to its high prevalence in both the developed and the developing countries, especially among young children. As currently approved vaccines are not protective enough and provide Th2-type immune responses, there is an urgent need to develop new vaccines. In the current study, we applied the C-terminal fragment of Clostridium perferingens enterotoxin (C-CPE) as a delivery system and F1S1 fragment (Filamentous hemagglutinin (F1) and subunit 1 of pertussis toxin (S1) of B. pertussis to design a novel chimeric protein in silico, to target Claudin-4 receptors in mice lung cells. To achieve this goal, the primary, secondary and tertiary structures of the fusion protein were evaluated and the interaction of this protein with Claudin-4 receptors was studied. Molecular dynamic (MD) simulation analysis was performed to investigate the physical movement of atoms in a fixed period. According to the results; the full-length fusion protein has consisted of 807 amino acid residues which could be classified as a stable protein. There was a convenient consistency between the 3D predicted structure and the secondary structure prediction. An acceptable percentage of the residues were also detected in the most favored and allowed regions for the model. Based on HADDOCK results, there were no considerable differences between the interactions and MD simulation analysis, indicating that the predicted structures were stable during the simulation. Altogether, the data reported in this study represents the first step toward developing a nasal vaccine candidate against B. pertussis infection. Communicated by Ramaswamy H. Sarma